Do you still offer nirmatrelvir–ritonavir to a vaccinated older adult with comorbidities and mild COVID-19 illness given recent trial data showing no reduction in hospitalization or mortality?

The Butler et al., PMID 42019019, paper published in the New England Journal of Medicine in 2026 reviewed 2 open-label trials from the United Kingdom and Canada (PANORAMIC and CanTreatCOVID) where higher-risk patients were randomly assigned to receive nirmatrelvir-ritonavir plus usual care versus us...